找不到产品?留下需求帮您找
一键询价UPCISCC090 人舌头鳞癌细胞 QCH766
一周
3500¥
KNS62 人肺支气管鳞状细胞癌 QCH767
一周
3500¥
HCC95 人肺腺癌细胞 QCH768
一周
3500¥
HARA 人肺腺癌细胞 QCH769
一周
3500¥
EPLC272H 人肺腺癌细胞 QCH770
一周
4000¥
NCI-H810 人非小细胞肺癌细胞 QCH771
一周
5000¥
HBL-1 人弥漫性大B细胞淋巴瘤 QCH772
一周
1800¥
FTC238 人滤泡状甲状腺癌细胞,肺转移 XY-H773
一周
3500¥
SNU-719 人胃癌细胞 QCH774
一周
3500¥
BT549+GFP+LUC 人乳腺癌细胞 QCH766GL
钦诚生物 | 一周
4500¥
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:DWK-1339 产品别名:见爱必信官网 英文别名:DWK-1339 靶点:Amyloid-β CAS:1018946-38-7 纯度:98% 外观:见爱必信官网 保存方法:store at -20℃ for one year(Powder) 描述:DWK-1339 is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease. 溶解性: 体外研究: DWK-1339 (MDR-1339) is an Aβ-aggregation inhibitor, and shows no significant inhibition a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50, 31.4 μM). DWK-1339 (3.1-50 μM) dose-dependently blocks the formation of Aβ aggregates, and disaggregates Aβ fibrils. DWK-1339 (1.5-10 μM) also protects cells from this Aβ-induced toxicity. 体内研究:DWK-1339 (MDR-1339) is an Aβ-aggregation inhibitor, and shows no significant inhibition a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50, 31.4 μM). DWK-1339 (3.1-50 μM) dose-dependently blocks the formation of Aβ aggregates, and disaggregates Aβ fibrils. DWK-1339 (1.5-10 μM) also protects cells from this Aβ-induced toxicity.
产品信息订购:
|